IL5 and allergic bronchopulmonary aspergillosis: An anti‐IL‐5 antibody, mepolizumab and an anti‐IL‐5 receptor antibody, benralizumab, have been reported to improve the condition of ABPA by diminishing IL‐5‐mediated eosinophilic airway inflammation.